PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Saxagliptin - Diabetes Mellitus

PAD Profile : Saxagliptin - Diabetes Mellitus

Keywords :
Gliptins, DPP-4, Dipeptylpeptidase -4 inhibitor, Type II
Brand Names Include :
Onglyza

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Important
Formulations :
  • Tablets
Important Information :
Existing patients would not be expected to change therapy unless appropriate to do so.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 June 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Area Prescribing Committee recommend:

sitagliptin (prescribed generically) as the preferred gliptin (DPP4) - GREEN traffic light status

linagliptin RESTRICTED USE - as an option in patients with deteriorating renal function where there is a risk that dose reduction of sitagliptin may not take place

Other gliptins (alogliptin, vildagliptin, saxagliptin) should NOT BE INITIATED in new patients
 

Associated BNF Codes

06. Endocrine System
06.01.02. Antidiabetic drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More